Your browser doesn't support javascript.
loading
Assessing the effects of antipsychotic medications on schizophrenia functional analysis: a postmortem proteome study.
Alnafisah, Rawan S; Reigle, James; Eladawi, Mahmoud Ali; O'Donovan, Sinead M; Funk, Adam J; Meller, Jaroslaw; Mccullumsmith, Robert E; Shukla, Rammohan.
Afiliação
  • Alnafisah RS; Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
  • Reigle J; Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, USA.
  • Eladawi MA; Biomedical Engineering Program, University of Toledo, Toledo, OH, USA.
  • O'Donovan SM; Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
  • Funk AJ; Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
  • Meller J; Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, USA.
  • Mccullumsmith RE; Neuroscience Graduate Program, University of Cincinnati, Cincinnati, OH, USA.
  • Shukla R; Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Neuropsychopharmacology ; 47(12): 2033-2041, 2022 11.
Article em En | MEDLINE | ID: mdl-35354897
ABSTRACT
Antipsychotic drugs (APDs) are effective in treating positive symptoms of schizophrenia (SCZ). However, they have a substantial impact on postmortem studies. As most cohorts lack samples from drug-naive patients, many studies, rather than understanding SCZ pathophysiology, are analyzing the drug effects. We hypothesized that comparing SCZ-altered and APD-influenced signatures derived from the same cohort can provide better insight into SCZ pathophysiology. For this, we performed LCMS-based proteomics on dorsolateral prefrontal cortex (DLPFC) samples from control and SCZ subjects and used statistical approaches to identify SCZ-altered and APD-influenced proteomes, validated experimentally using independent cohorts and published datasets. Functional analysis of both proteomes was contrasted at the biological-pathway, cell-type, subcellular-synaptic, and drug-target levels. In silico validation revealed that the SCZ-altered proteome was conserved across several studies from the DLPFC and other brain areas. At the pathway level, SCZ influenced changes in homeostasis, signal-transduction, cytoskeleton, and dendrites, whereas APD influenced changes in synaptic-signaling, neurotransmitter-regulation, and immune-system processes. At the cell-type level, the SCZ-altered and APD-influenced proteomes were associated with two distinct striatum-projecting layer-5 pyramidal neurons regulating dopaminergic-secretion. At the subcellular synaptic level, compensatory pre- and postsynaptic events were observed. At the drug-target level, dopaminergic processes influenced the SCZ-altered upregulated-proteome, whereas nondopaminergic and a diverse array of non-neuromodulatory mechanisms influenced the downregulated-proteome. Previous findings were not independent of the APD effect and thus require re-evaluation. We identified a hyperdopaminergic cortex and drugs targeting the cognitive SCZ-symptoms and discussed their influence on SCZ pathology in the context of the cortico-striatal pathway.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Neuropsychopharmacology Assunto da revista: NEUROLOGIA / PSICOFARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Neuropsychopharmacology Assunto da revista: NEUROLOGIA / PSICOFARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos